Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/angiogenesis-and-antiangiogenic-treatment-in-lung-cancer-Q8h03WBx9t
References (35)
-
AA Vaportciyan, JC Nesbitt, JS Lee (2000)
Cancer Medicine -
JL Pujol, JL Breton, R Gervais (2006)
A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease SCLC patients after response to chemotherapy: an intergroup study FNCLCC cleo 04-IFCT 00-01Proc Am Soc Clin Oncol, 24
-
J. Pujol, J. Breton, R. Gervais, M. Tanguy, E. Quoix, P. David, H. Janicot, A. Depierre, S. Gameroff, D. Maraninchi (2006)
A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT): An intergroup study FNCLCC Cleo04 - IFCT 00-01.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
M. Socinski, S. Novello, J. Sánchez, J. Brahmer, R. Govindan, C. Belani, J. Atkins, H. Gillenwater, C. Palleres, R. Chao (2006)
Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
F. Shepherd (2005)
A targeted approach to reducing lung cancer mortality.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 14
-
J. Bréchot (2003)
L'angiogenèse et son inhibition dans le traitement des cancers bronchiques, 6
-
L. Hyde, C. Hyde (1974)
Clinical manifestations of lung cancer.Chest, 65 3
-
Taiana Ja, Aracama Va, E. Schieppati (1952)
[Cancer of the lung].The Journal of the International College of Surgeons, 17 4
-
C. Ushijima, Shuichi Tsukamoto, Koji Yamazaki, Ichiro Yoshino, Kenji Sugio, K. Sugimachi (2001)
High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression.Lung cancer, 34 2
-
R Lilenbaum, R Axerold, S Thomas (2006)
Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2Proc Am Soc Clin Oncol, 24
-
RB Natale, D Bodkin, R Govindan (2006)
ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trialProc Am Soc Clin Oncol, 24
-
R. Natale, D. Bodkin, R. Govindan, B. Sleckman, N. Rizvi, A. Capó, P. Germonpré, P. Stockman, S. Kennedy, M. Ranson (2006)
ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
J. Folkman (1971)
Transplacental carcinogenesis by stilbestrol.The New England journal of medicine, 285 7
-
U Gatzemeier, G Blumenschein, F Fosella (2006)
Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinomaProc Am Soc Clin Oncol, 24
-
M. Bariéty (1967)
Les carcinomes bronchiques primitifs -
A Sandler (2005)
Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern cooperative oncology group (ECOG) Trial E4599Proc Am Soc Clin Oncol, 23
-
A. Sandler, R. Herbst (2006)
Combining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor PathwaysClinical Cancer Research, 12
-
A. Meert, M. Paesmans, B. Martin, P. Delmotte, T. Berghmans, J. Verdebout, J. Lafitte, C. Mascaux, J. Sculier (2002)
The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysisBritish Journal of Cancer, 87
-
J. Schiller, D. Harrington, C. Belani, C. Langer, A. Sandler, J. Krook, Junming Zhu, David Johnson (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.The New England journal of medicine, 346 2
-
D. Morgensztern, R. Govindan (2006)
Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474Expert Review of Anticancer Therapy, 6
-
A. Sandler, R. Gray, J. Brahmer, A. Dowlati, J. Schiller, M. Perry, David Johnson (2005)
Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599Journal of Clinical Oncology, 23
-
David Johnson, L. Fehrenbacher, W. Novotny, R. Herbst, J. Nemunaitis, D. Jablons, C. Langer, R. Devore, J. Gaudreault, L. Damico, E. Holmgren, F. Kabbinavar (2023)
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 41
-
J. Heymach, B. Johnson, J. Rowbottom, P. Fidias, Charles Lu, D. Prager, J. Roubec, E. Csada, I. Dimery, R. Herbst (2005)
A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLCJournal of Clinical Oncology, 23
-
(1971)
tissue in associated with tumor progression -
U. Gatzemeier, G. Blumenschein, F. Fosella, R. Simantov, J. Elting, D. Bigwood, F. Cihon, Martin Reck (2006)
Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
B. Giantonio, P. Catalano, N. Meropol, P. O'dwyer, E. Mitchell, S. Alberts, M. Schwartz, A. Benson (2005)
High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200Journal of Clinical Oncology, 23
-
R. Lilenbaum, R. Axerold, S. Thomas, A. Dowlati, L. Seigel, D. Albert, C. Duym, D. Bodkin (2006)
Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
AJ Alberg, JM Samet (2003)
Epidemiology of lung cancerChest, 123
-
N. Peacock, D. Spigel, M. Mainwaring, Dana Thompson, L. Simons, M. Rubin, M. Mccleod, W. Harwin, F. Schreiber, D. Yardley (2007)
Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2+ pts) as first-line treatment in metastatic breast cancerJournal of Clinical Oncology, 25
-
R. Herbst, B. Johnson, J. Rowbottom, P. Fidias, Charles Lu, D. Prager, J. Roubec, E. Csada, I. Dimery, J. Heymach (2005)
O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trialLung Cancer, 49
-
MA Socinski, S Novello, JM Sanchez (2006)
Efficacy and of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC) : preliminary results of a multicenter phase II trialProc Am Soc Clin Oncol, 24
-
an intergroup study FNCLCC cleo 04- IFCT 00-01 -
A. Alberg, M. Brock, J. Samet (2005)
Epidemiology of lung cancer: looking to the future.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 14
-
J. Folkman (1971)
Tumor angiogenesis: therapeutic implications.The New England journal of medicine, 285 21
-
P.E. Baldry, B. Golberg, E. Moyes, P.G. Arblaster, P.F. Jones, T.M. Wilson, R. Grenville-Mathers, H. Trenchard, D. Paradise (1960)
Bronchial CarcinomaInternational Journal of Clinical Practice, 14
- Publisher
- Springer Journals
- Copyright
- Copyright © 2006 by Springer-Verlag
- Subject
- Medicine & Public Health; Biomedicine general; Oncology
- ISSN
- 1776-2596
- eISSN
- 1776-260X
- DOI
- 10.1007/s11523-006-0031-4
- Publisher site
- See Article on Publisher Site
Abstract
Angiogenic factors released by cancer cells increase structurally and functionally abnormal tumor micro-vascularization, resulting in metastases and progressive disease. Such diffusible factors bind to specific receptors of endothelial cells and activate the angiogenic signal pathway. Treatments with antiangiogenic monoclonal antibodies (e.g., bevacizumab) or using small molecules with anti-tyrosine kinase activity (e.g., sunitinib, sorafenib, ZD6474, erlotinib, or thalidomide) can block angiogenic signaling, lower blood tumoral irrigation, and improve chemotherapy distribution. Numerous studies have shown that a combination of biotherapy and chemotherapy can improve medical management of patients with advanced or metastatic non-small cell lung carcinomas. Biotherapy combination approaches also yield encouraging results promoting the development of targeted antitumor drugs.
Journal
Targeted Oncology – Springer Journals
Published: Sep 23, 2006